ESH 2017 | Highly targeted medication for AML

Andrew Wei

There have been large strides in the treatment of leukemia; however, current methods lack specificity. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Andrew Wei, MBBS, PhD, FRACP, FRCPA from Alfred Hospital and Monash University, Melbourne, Australia discusses the use of targeted medication to inhibit anti-apoptotic proteins and how this could reduce toxicity.

Share this video